Source comparison
Tesamorelin + Ipamorelin Blend for Fat Loss: Protocol Comparison
Before implementing any research protocol, understanding the dosing, timing, and reconstitution variables is essential. The table below compares the key parameters for tesamorelin and ipamorelin within a typical fat-loss research stack. Mechanism GHRH receptor
This comparison does not assign a generated winner or score.
- Before implementing any research protocol, understanding the dosing, timing, and reconstitution variables is essential. The table below compares the key parameters for tesamorelin and ipamorelin within a typical fat-loss research stack.
- Mechanism
- GHRH receptor agonist (anterior pituitary)
- Ghrelin receptor agonist (GHS-R1a)
- Complementary pathways. One increases GH pulse amplitude, the other increases frequency
- Typical Dose
- 1-2 mg daily
- 200-300 mcg per injection, 1-2x daily
- Tesamorelin dosed once daily; ipamorelin often split into AM/PM doses for sustained pulsatile effect
- Half-Life
- 26-38 minutes (peptide), GH release peaks 30-45 min
- ~2 hours (peptide), GH peaks 30-60 min
- Both have short plasma half-lives. Timing matters for receptor activation windows
- Fat Loss Selectivity
- Visceral adipose tissue (VAT) preferentially reduced 15-18% in trials
- General GH-mediated lipolysis; no specific VAT selectivity demonstrated
- Tesamorelin is the visceral fat specialist; ipamorelin amplifies total GH output
- Cortisol Impact
- Minimal. GHRH pathway does not activate HPA axis
- None. Selective GHS-R1a activation without ACTH or cortisol elevation
- Critical for long-term use; cortisol elevation would negate fat-loss and muscle-preservation goals
- Reconstitution
- Lyophilized powder reconstituted with bacteriostatic water, 2 mg/mL typical
- Lyophilized powder reconstituted with bacteriostatic water, 200-500 mcg/mL typical
- Both require refrigeration at 2-8°C post-reconstitution; use within 28 days
- Clinical Evidence
- Phase III RCTs in HIV lipodystrophy; 26-week data with CT-measured VAT reduction
- Phase II PK/safety data; limited long-term body composition trials
- Tesamorelin has stronger fat-loss evidence; ipamorelin has proven GH release and safety profile
- Injection Timing
- Typically evening (before bed) to align with natural GH secretion rhythm
- AM and/or PM dosing; some protocols dose pre-workout for additional lipolytic effect
- Timing aligns with circadian GH patterns. Evening dosing mimics physiological nocturnal GH surge